GLTO Galecto, Inc.
USHealthcareAs of 2026-06-04 12:02
Why GLTO matters now
Galecto, Inc. (GLTO) is a US stock in Healthcare. The latest InvestLog snapshot shows $21.58 with -3.36% on the session and $34.5M in market capitalization; recent performance reads 1-month -10.23% and YTD -6.21%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-27.8M, and EPS of $-17.39. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.5%.
The latest indexable market news headline is "What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $45.00; recent insider activity includes Fairmount Funds Management LLC filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.06
P/S
0.00
EV/EBITDA
-3.30
DCF Value
$176.42
FCF Yield
-1.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-122.6%
ROA
-43.9%
ROIC
-46.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-27.8M | $-17.39 |
| Q4 2025 | $0.00 | $-200.7M | $2.31 |
| FY 2025 | $0.00 | $-209.8M | $-3.71 |
| Q3 2025 | $0.00 | $-3.1M | $-2.36 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$43.67
Target (Median)
$45.00
Target Range
$40.00 - $46.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.57
Galecto, Inc. is a clinical-stage biotechnology company focused on creating new therapeutic agents for a range of illnesses, including fibrotic conditions, cancer, and inflammation. Its most advanced investigational drug, GB2064, is currently undergoing Phase IIa clinical studies to treat myelofibrosis. The company is also developing GB0139, an inhalable compound that targets galectin-3, which is in Phase IIb trials for severe fibrotic lung disorders, such as idiopathic pulmonary fibrosis (IPF)—a serious and progressively worsening lung disease. Additionally, Galecto is advancing GB1211, a selective oral galectin-3 inhibitor, with ongoing Phase IIa trials for cancer and Phase Ib/IIa trials for fibrosis. Founded in 2011, Galecto, Inc. is headquartered in Boston, Massachusetts.